Ginkgo Bioworks (DNA) CFO sells 972 shares after RSU vesting

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. Chief Financial Officer Steven P. Coen reported RSU vesting and a small share sale. On January 16, 2026, RSUs covering 587, 156, and 1,062 units were converted into the same number of Class A common shares at an exercise price of $0 per share, reflecting equity awards that had been vesting over time. After these conversions, he held 9,293 Class A shares directly. On January 20, 2026, he sold 972 Class A shares at $8.917 per share, leaving him with 8,321 shares. According to the footnotes, the sale was made to cover tax withholding obligations related to the vesting of restricted stock and RSUs and did not represent a discretionary trade.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coen Steven P.

(Last) (First) (Middle)

C/O GINKGO BIOWORKS HOLDINGS, INC.

27 DRYDOCK AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [ DNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/16/2026		M(1)		587	A	(1)	8,075	D
Class A Common Stock	01/16/2026		M(1)		156	A	(1)	8,231	D
Class A Common Stock	01/16/2026		M(1)		1,062	A	(1)	9,293	D
Class A Common Stock	01/20/2026		S(2)		972	D	$8.917	8,321	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/16/2026		M(1)			587	(3)	(3)	Class A Common Stock	587	(1)	9,405	D
Restricted Stock Units	(1)	01/16/2026		M(1)			156	(4)	(4)	Class A Common Stock	156	(1)	4,067	D
Restricted Stock Units	(1)	01/16/2026		M(1)			1,062	(5)	(5)	Class A Common Stock	1,062	(1)	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

3. The RSUs vest as follows: 25% of the underlying shares vested on May 1, 2024, then 36 equal monthly installments thereafter.

4. The RSUs vest as follows: 2/48ths of the underlying shares vested on May 1, 2024, then 46 equal monthly installments thereafter.

5. The RSUs vest as follows: 25% vested on April 16, 2025; 25% vested on July 16, 2025; 25% vested on October 16, 2025; and 25% vested on January 16, 2026.

Remarks:

Chief Financial Officer

	/s/ Karen Tepichin, Attorney-in-Fact	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did DNA executive Steven P. Coen report?

Steven P. Coen, an officer of Ginkgo Bioworks Holdings, Inc. (DNA), reported RSU conversions into Class A common stock on January 16, 2026 and a small share sale on January 20, 2026.

How many Ginkgo Bioworks (DNA) shares did the CFO sell?

On January 20, 2026, the CFO sold 972 shares of Class A common stock at a price of $8.917 per share.

Why were Ginkgo Bioworks (DNA) shares sold in this Form 4?

The footnotes state the 972 shares were sold to cover tax withholding obligations related to the vesting of restricted stock and restricted stock units and did not represent a discretionary trade.

What RSU activity did the DNA CFO report on January 16, 2026?

On January 16, 2026, RSUs for 587, 156, and 1,062 units were converted into an equal number of Class A common shares at an exercise price of $0 per share.

How many Ginkgo Bioworks (DNA) shares did the CFO hold after the transactions?

Following the RSU conversions and the tax-related sale, the CFO directly held 8,321 shares of Ginkgo Bioworks Class A common stock.

What do the RSU vesting schedules disclosed for DNA indicate?

The footnotes explain that different RSU grants vest over time, including one grant with 25% vesting on May 1, 2024 followed by 36 monthly installments, and another with portions vesting on April 16, 2025, July 16, 2025, October 16, 2025, and January 16, 2026.